Thursday, 29 October 2026 Every NSE & BSE announcement, by company
ALFA Filings Every announcement, straight from the exchange
Product Launch

Glenmark Pharmaceuticals Product Launch

Glenmark launched Vancomycin Hydrochloride for Injection in the U.S. market. The product targets a ₹363.84 Crore market, strengthening the company's injectable portfolio and presence.

Key figures
Value₹363.8 Cr
Execution period12-month period ending March 2026
Source

NSE filing, NSE: GLENMARK. Summary written from the filing by ALFA Finder's alert engine.

Read the filing ↗

Glenmark Pharmaceuticals Ltd: key numbers

Share price
₹2,300.00
Market cap
₹64,912 Cr
Revenue (annual)
₹16,983 Cr
Net profit (annual)
₹1,362 Cr
P/E (TTM)
36.1×Sector 46.1×
Promoter holding
46.65%+0.00% QoQ
FII holding
21.51%Current quarter

Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.

More from Glenmark Pharmaceuticals Ltd

All →
08:50 IST BSE
Product Launch

Glenmark Pharmaceuticals Product Launch

Glenmark Pharmaceuticals launched RYALTRIS® nasal spray in Brazil to treat moderate to severe allergic rhinitis, expanding its global respiratory product footprint in Latin America.

Other product launch announcements

All →